Dry AMD: What You Need to Know About Age-Related Macular Degeneration

In the early stage of dry AMD, most people have no visual complaints at all. Drusen are present under the retina, but they have not yet affected the light-sensing cells enough to cause noticeable changes. This stage is typically discovered during a routine dilated eye exam.

Because there are no symptoms, regular eye exams after age 50 are especially important. Detecting dry AMD early gives you and your eye doctor time to monitor for progression and make lifestyle changes that may help slow it.

As dry AMD advances to the intermediate stage, some people begin to notice mild central blurring, reduced contrast, or difficulty seeing in dim lighting. Reading may require brighter light than it used to, and colors may seem less vivid than before.

These changes can be easy to dismiss as normal aging, but they are worth discussing with your eye doctor. Imaging at this stage can reveal how much drusen have grown and whether any early thinning has begun.

Geographic atrophy causes patches of retinal cells to die, creating a blank or blurry area in your central vision. Reading, recognizing faces, and driving become progressively more difficult as the affected area expands.

The blank spot often has well-defined edges. It may first appear as difficulty reading a line of text or seeing a face clearly. Your eye doctor uses specialized imaging to measure how quickly the atrophic area is growing and to guide treatment decisions.

Yes, and this is one of the most important things to watch for. Dry AMD can convert to wet AMD at any stage, including early stages. The key warning signs are sudden distortion, new waviness in straight lines, or a dark spot that appears without gradual buildup. These symptoms should prompt a same-day call to your eye doctor, not a wait-and-see approach, because wet AMD can cause rapid vision loss if not treated promptly.

No. The research supporting AREDS2 supplements was conducted in people with intermediate dry AMD or late AMD in one eye. The studies did not show a benefit for people with early dry AMD. If you are in the early stage, taking AREDS2 supplements is not currently recommended and should be discussed with your eye doctor before you start them on your own. Your doctor will base the recommendation on your actual drusen pattern and stage, not just your age or family history.

The pace varies considerably from person to person. Some people remain in the intermediate stage for many years with minimal change, while others develop geographic atrophy within a few years of diagnosis. Factors that influence your rate of progression include drusen size and pattern, pigment changes in the macula, genetics, smoking history, and cardiovascular health. This is why personalized monitoring, rather than a one-size-fits-all schedule, is so important.

Dry AMD does not cause total blindness. Even in advanced geographic atrophy, your peripheral (side) vision remains intact. You may lose the ability to read standard print, recognize faces clearly, or drive safely, but you will still be able to see and navigate your environment. Low vision specialists and rehabilitation programs offer tools and strategies that help people with late-stage AMD continue to live independently and perform daily activities.

The right schedule depends on your stage and how stable your condition appears on imaging. Early dry AMD may be monitored every 12 to 24 months. Intermediate or late dry AMD often requires visits every 6 to 12 months, and sometimes more frequently if your imaging shows active change. Your eye doctor sets your monitoring schedule based on your specific results rather than a standard timeline. Daily Amsler grid checks at home fill the gap between appointments.

Research into dry AMD treatments is moving quickly. In addition to the FDA-approved therapies for geographic atrophy, clinical trials continue to explore new approaches. The best way to stay current is to ask your eye doctor directly at each visit whether anything new applies to your stage and circumstances. Your doctor can also advise whether a referral to a retinal subspecialist for a second opinion or trial participation would be worthwhile.